Royal Bank of Canada
PXMD

Royal Bank of Canada’s PaxMedica, Inc. Common Stock PXMD Stock Holding History

Royal Bank of Canada’s Portfolio PXMD Stock Details PXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4
Closed – – 7978
2022
Q3 		$0 Buy
+4
New +$226 ﹤0.01% 8074

Other funds holding PXMD

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada's PXMD Position: Q4 2022 in Review

Royal Bank of Canada sold out of PaxMedica, Inc. Common Stock (PXMD) in Q4 2022, closing a stake of 4 shares.

Royal Bank of Canada first reported a position in PXMD in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 8 funds tracked by Wall St. Rank hold PXMD as of Q4 2022.

  • Royal Bank of Canada reported no remaining PaxMedica, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 4 PaxMedica, Inc. Common Stock shares in Q4 2022.
  • Royal Bank of Canada first reported a position in PaxMedica, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Royal Bank of Canada's PaxMedica, Inc. Common Stock position peaked at $0 in Q3 2022.
  • 8 funds tracked by Wall St. Rank held PaxMedica, Inc. Common Stock as of Q4 2022.

Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.